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Abstract
Contagious disease is a major threat to survival, and the cost of relying on the immune system to 
defeat pathogens is high; therefore, behavioral avoidance of contagious individuals is arguably an 
adaptive strategy. Animal findings demonstrate the ability to detect and avoid sick individuals by 
the aid of olfactory cues, and a recent study indicated that human axillary odor also becomes more 
aversive as a function of immune activation. By injecting healthy human participants with lipo-
polysaccharide (0.6 ng/kg body weight) to experimentally induce inflammation, this study demon-
strates that natural daily rhythms of urine odor—its perceived dimensions and volatile profile—are 
altered within hours of inflammation onset. Whereas healthy human urine decreases in averseness 
over the course of a single day, inflammation interrupts this process and results in an increased 
urine odor averseness and an altered volatile composition. These results support the notion that 
subtle and early cues of sickness may be detected and avoided, thereby complementing the im-
mune system in its role of keeping us alive and healthy.
Key words:  behavioral immune system, human, inflammation, odor, sickness, urine
Introduction
Throughout evolution, one of the more common causes of death 
has been infections (Jones et al. 2012). The threat posed by infec-
tion for living organisms is reflected in the fact that genes related 
to immunity are evolutionary hotspots, with pathogens as a leading 
cause of change in humans (Fumagalli et al. 2011). Recent evidence 
suggests that selective pressures have also shaped a behavioral de-
fense against disease (Schaller and Duncan 2007). Indeed, across 
phyla, behavior adjustment would represent a first line of defense 
against infection, preventing or reducing parasite load via the de-
tection of sickness cues and the initiation of avoidance behaviors 
(Curtis 2014), as well as sickness behaviors, to increase recuperation 
once infected (Dantzer et al. 2008).
It is becoming increasingly clear that most mammals—includ-
ing humans—rely on olfaction for communication (Wyatt 2014). 
Among the cues communicated by endogenous volatile compounds 
are an individual’s age (Osada et al. 2003; Mitro et al. 2012), gen-
etic composition (Eggert et al. 1998), kin status (Lundstrom et al. 
2009), and emotional state (de Groot et  al. 2012). In addition, a 
number of nonhuman animal studies have demonstrated that urine 
from immune-activated individuals contains volatile sickness cues 
and that these cues initiate an avoidance response in conspecifics 
(Kavaliers and Colwell 1995a, 1995b; Kiesecker et al. 1999; Ehman 
and Scott 2001, 2002; Arakawa et al. 2011; Kimball et al. 2014). 
The variety of immune challenges used in these studies, from para-
sites to viruses, including vaccines, suggests that the mechanisms 
regulating the release of such communicative volatile metabolites are 
not necessarily disease-specific. Furthermore, although these volatile 
cues could be generated at any stage of the innate or adaptive im-
mune responses, their rapid availability post-administration, within 
hours of pathogen exposure, appears to exclude adaptive immunity. 
The quick-acting, general, innate immune response, therefore, is a 
strong contender for regulating such cues (Kimball et al. 2014).
A common experimental model of the innate immune system’s 
acute inflammatory response utilizes injection of the bacterial endo-
toxin lipopolysaccharide (LPS), a potent, nonspecific activator of the 
innate immune system (Dantzer et al. 2008; Beutler 2009). Toll-like 
receptor 4 (TLR4), expressed on sentinel cells, recognizes and binds 
LPS, resulting in the production of interleukin-1β (IL-1β) pro-inflam-
matory cytokines. Thereafter, IL-1β triggers its own synthesis as well 
as that of additional, mainly pro-inflammatory cytokines, tumor ne-
crosis factor-α (TNF-α) and interleukin-6 (IL-6), and anti-inflam-
matory cytokines, such as interleukin-10 (IL-10) (Karshikoff 2015). 
This inflammatory cascade peaks and subsides within 4–6 h of LPS 
injection. Rodents injected with LPS are perceptually discriminable 
to conspecifics from their saline-injected counterparts, as evidenced 
by increased avoidance behavior (Renault et al. 2008; Arakawa et al. 
2009). Furthermore, smelling only the soiled bedding of LPS- versus 
saline-injected conspecifics evoked a similar heightened avoidance 
response, indicating that detectible odor cues of acute inflammation 
are present in the urine volatile profile (Arakawa et al. 2009, 2010; 
Boillat et al. 2015). Further support for the causal role of innate im-
mune activation in the generation of this aversive odor cue comes 
from data demonstrating that infusion of pro-inflammatory IL-1β 
was sufficient to induce this heightened avoidance response and that 
infusion of anti-inflammatory IL-10 was sufficient to suppress it 
(Arakawa et al. 2010). Together, these studies demonstrate that non-
human animals are capable of detecting cues of inflammation—not 
just infection—from the urine odors of conspecifics.
Evidence for a human capacity to communicate and detect con-
specific sickness cues comes to a large extent from observational re-
search and anecdotal reports that infectious and metabolic diseases 
emit disease-specific odor profiles (Penn and Potts 1998; Shirasu and 
Touhara 2011). However, these reports do not exemplify the inflam-
mation detection necessary for successful behavioral avoidance of 
infected conspecifics but rather detection of more advanced disease 
states. Moreover, these data are often confounded by selection biases 
involving diet, lifestyle, and medication factors that may also affect 
endogenous odor (Parma et  al. 2017). To bypass such confounds, 
we previously used an experimental LPS model of acute inflamma-
tion in otherwise healthy individuals to demonstrate that humans—
like other mammals—are able to detect cues of acute inflammation. 
Participants found the axillary odors of human conspecifics col-
lected during LPS-induced inflammation to be significantly more 
unpleasant, intense, and unhealthy than those collected from the 
same individuals after injection with a saline placebo (Olsson et al. 
2014). Furthermore, we recently demonstrated that such axillary ol-
factory sickness cues were processed by a cortical network including 
primary and secondary olfactory areas in the brain and tended to 
reduce the likability of simultaneously presented faces (Regenbogen 
et  al. 2017). Thus, axillary odor cues can provide information on 
the inflammatory status in humans, but whether similarly detectable 
cues exist in human urine odor is not yet known.
Studies of nonhuman animals have assessed the changes in en-
dogenous odor caused by acute inflammation and the behavioral ef-
fects they induce in conspecifics using, with few exceptions, urine—a 
volatile source seldom studied in humans. The numerous anatomical 
and cultural adaptations that separate modern Homo sapiens from 
primates and even from earlier members of our own species have 
limited the contexts in which (and diminished the frequency with 
which) humans encounter conspecifics’ urine. However, although the 
value to modern humans of any cue in conspecific urine odor may be 
limited, the presence or absence of a detectable cue with the poten-
tial to mediate avoidance is an independent question. Knowledge of 
the selection pressures favoring disease avoidance, the demonstrated 
ability of nonhuman animals to detect inflammation in urine volat-
iles, and the relatively recent shared ancestry of these animals and 
humans, in parallel with knowledge of the demonstrated human 
ability to detect inflammation in conspecific axillary volatiles and of 
the fact that the profile of volatile compounds in human urine over-
laps significantly with that emitted by the human axillae (Penn et al. 
2007), make human urine a promising potential source for cues of 
inflammation.
The aims of this study were 2-fold: first, we sought to determine 
whether humans can detect an acute inflammatory response in urine 
volatiles; second, we sought to identify potential volatile markers of 
the acute inflammatory response. Donors were injected with either 
LPS or a saline placebo, and urine was collected both before and 
after injection. To facilitate a double-blind design, we opted to use a 
low dose of LPS to induce a systemic increase in pro-inflammatory 
cytokines while minimizing overt behavioral and physical symp-
toms of sickness. The odor of urine samples was assessed by healthy 
human participants to identify perceptual differences induced by LPS 
treatment. Samples were also analyzed chemically by gas chroma-
tography–mass spectrometry (GC-MS) to identify changes in vola-
tile metabolites with the potential to discriminate LPS from Placebo 
treatments. We hypothesized that the changes to urine odor and 
volatile profile induced by LPS and Placebo treatment would be dis-
criminable by perceptual and chemical assays, respectively, thereby 
indicating that human urine contains detectable cues of acute inflam-
mation with the potential to mediate behavioral avoidance.
Materials and methods
Endotoxin treatment and sample collection (urine 
and plasma) from donors
Thirty-three healthy volunteers participated as urine donors after 
providing informed written consent, 20 in the LPS condition (13 
women) and 13 in the Placebo condition (8 women). Donors were 
right-handed, medication-free, nonsmokers without any history of 
drug abuse, chronic pain, or psychiatric disorders. All women were 
premenopausal, and usage of hormonal contraceptives was allowed. 
Beginning 12 h prior to the first sample collection, donors followed 
a restricted diet free of food known to scent urine. Treatment and 
sample collection (urine and plasma) were performed using a ran-
domized, double-blind, between-subjects design under the supervi-
sion of an attending physician in a hospital environment (Karshikoff 
et  al. 2015). An injection of either 0.6  ng LPS/kg body weight 
(Escherichia coli, Lot nr. G3E0609; United States Pharmacopeia) 
or phosphate-buffered saline solution was delivered intravenously 
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at approximately 10:00 AM. Selection of a low LPS dosage facili-
tated maintenance of the double-blind design for the duration of the 
subsequent sample collection period. Urine samples were collected 
from each donor approximately 1 h pre- and 4 h postinjection in 
plastic cups and then immediately transferred to glass storage vials. 
The time elapsed between pre- (Pre) and postinjection urine sample 
(Post) collections did not differ significantly between conditions, 
t(23.49) = 0.42, P = 0.677 (LPS: 4.5 ± 0.8 h; Placebo: 4.4 ± 0.8 h). 
Plasma samples were collected from each donor preinjection (base-
line, 0 h) and at 1.5, 3.5, and 5 h postinjection in 10 mL ethylen-
ediaminetetraacetic acid (EDTA) plasma tubes (BD Vacutainer) and 
were cold centrifuged at 1500  × g for 20  min. Urine and plasma 
samples were frozen at −70 °C on location immediately after collec-
tion and thawed 1 h before usage in either the chemical or behav-
ioral assay. Urine samples were kept in freezers at −70 °C for the 
entirety of the 2.25–2.75 year storage period between collection and 
analysis, except for the duration of express shipment to the United 
States, during which they were kept frozen on dry ice. All aspects of 
the treatment and sample collection portions of the experiment were 
approved by the Regional Ethical Review Board and performed at 
the Karolinska University Hospital (Solna, Sweden) in accordance 
with the Declaration of Helsinki on biomedical studies involving 
human subjects.
Measures of an inflammatory response in donors
Plasma samples were analyzed using the MILLIPLEX MAP high-sen-
sitivity human cytokine kit (Millipore Corporation) with Luminex 
xMAP methodology (Luminex Corporation). Levels of TNF-α, IL-6, 
IL-8, and IL-10 were measured at each collection time, and the area 
under the curve (AUC) was calculated for each cytokine to verify 
the presence and absence of an inflammatory response in LPS and 
Placebo donors, respectively.
Sensory assessment participants
Twenty-one participants (13 women, 26.2  ±  3.6  years, range: 
19–32 years) performed the sensory assessment portion of the ex-
periment after providing informed written consent. Participants 
were medication-free nonsmokers without any history of con-
sciousness loss resulting from head trauma or hormonal, auto-
immune, neurological, or psychiatric disorders–all factors with the 
potential to affect olfactory processing (Boesveldt et  al. 2011). To 
verify that no participant had functional anosmia, a 6-item, 4-al-
ternative, forced-choice odor identification test, selected from the 
original 40-item Monell Extended Sniffin’ Sticks Identification Test 
(MONEX-40) (Freiherr et al. 2012), was administered. All partici-
pants correctly identified 4 or more odors, corresponding to a bi-
nomial probability significantly better than chance (P < 0.05). On 
the day of testing, participants used no scented body products and 
refrained from chewing gum and eating or drinking anything but 
water for the hour immediately prior to testing. All aspects of the 
sensory assessment portion of the experiment were approved by the 
institutional review board of the University of Pennsylvania and per-
formed at the Monell Chemical Senses Center (Philadelphia, United 
States) in accordance with the Declaration of Helsinki on biomedical 
studies involving human subjects.
Sensory assessment of donor urine samples
Sensory testing was performed in rooms engineered for odor testing, 
equipped with a high air exchange rate to prevent lingering odors and 
red fluorescent lighting to prevent potential differences in stimulus 
color from  influencing sensory assessments. Urine from 27 donors, 
15 LPS (11 women, 26.5 ± 6.0 years, range: 20.6–41.0 years) and 12 
Placebo (7 women, 27.6 ± 4.9 years, range: 20.5–35.2 years), was used 
in the sensory assessment portion of the experiment as, due to suspi-
cion of contamination (e.g., noncompliance with food and hygiene 
instructions), urine from 6 donors was excluded. Donor age did not 
differ significantly between conditions [t(24.97) = 0.51, P = 0.612]. 
(Routine outlier identification in the GC-MS data later indicated that 
there were no outliers among the urine samples from 4 of the 6 ex-
cluded donors, and these were subsequently included in the chemo-
metric analyses.) For sensory assessment, urine samples from LPS and 
Placebo donors were divided into multiple stimulus “triplets,” each 
comprising 1 Post and 2 identical Pre volumes of 1.0  mL urine in 
20  mL glass vials. Urine samples were vortexed before aliquoting 
to prevent any effects of sample fractionation. Each participant per-
formed the same perceptual ratings and discrimination tasks on 3 LPS 
triplets (9 vials) and 3 Placebo triplets (9 vials) in 2 counterbalanced 
blocks of the testing session. In other words, each participant smelled 
Pre and Post urine samples from 3 LPS and 3 Placebo donors of the 
same sex. Stimulus triplets were pseudorandomly assigned to a partici-
pant and were never reused for any other participant.
In the 3-alternative, forced-choice discrimination tasks, par-
ticipants were instructed to, on each of 11 trials, choose the odd 
one out of the 3 vials of a donor triplet, 1 vial with a donor’s Post 
urine sample (target) and 2 with the same donor’s Pre urine samples 
(lures). Trial order was pseudorandomized among the 3 donor trip-
lets, either LPS or Placebo, depending on the experimental block, 
such that 2 of the 3 triplets were used on 4 trials, each, and 1 of the 3 
triplets was used on only 3 of the 11 trials. Using intra-donor triplets 
precluded the possibility of discrimination based on donor identity, 
at which humans are adept (Lundström et al. 2008, 2009), rather 
than treatment, thereby preventing a sizeable confound.
Perceptual ratings of odor pleasantness, intensity, disgustingness, 
and donor sickness were performed on visual analog scales (VAS). 
Perceived odor pleasantness is widely believed to be the primary di-
mension of olfactory perceptual space and may be the basis of olfac-
tory functioning (Yeshurun and Sobel 2010). Perceived intensity was 
chosen to assess the contribution of a quantitative, as opposed to 
qualitative, treatment-induced change in urine odor, and perceived 
disgust was selected on the basis of its hypothesized evolution as a 
disease-avoidance mechanism (Oaten et al. 2009). Duplicate ratings 
were collected in 2 rounds, each with a unique randomized order 
of vials from the 3 stimulus triplets of that block. Rating scales for 
perceived intensity, disgustingness, and sickness ranged from 0 to 10, 
and the minima and maxima were defined as “Not at all” and “Most 
imaginable,” respectively. The scale for perceived pleasantness rat-
ings ranged from −5 to 5, defined as “Most unpleasant imaginable” 
and “Most pleasant imaginable,” respectively, and it contained a 
midpoint defined as “Neutral.”
Chemometric analyses of donor urine samples
Headspace GC-MS and subsequent chromatographic data ana-
lyses assessed the potential differences in the profiles of volatile (i.e., 
odorous) organic compounds of urine from 33 LPS and Placebo 
donors. Triplicate 25 µL urine aliquots from each donor were trans-
ferred to individual 20  mL glass sample vials and fortified with 
10 µL of an aqueous l-carvone solution so that 80.2 ng was precisely 
delivered to each sample. Control samples consisted of “blank” 
vials, all of which lacked urine and contained only the aqueous l-
carvone solution. All samples were subjected to headspace analysis 
using a HT3 dynamic headspace analyzer (Teledyne Tekmar) out-
fitted with Supelco Trap K Vocarb 3000 thermal desorption trap 
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(Sigma-Aldrich). Each sample vial was maintained at 40 oC and 
swept with helium for 45 min (flow rate of 75 mL/min), and the 
volatiles were collected on the trap. Trap contents were desorbed 
at 265 oC directly into an ISQ single quadrupole GC-MS (Thermo 
Scientific) equipped with a 30 m × 0.25  mm I.D. Stabilwax-DA 
fused-silica capillary column (Restek). The GC oven program had an 
initial temperature of 40 oC (held for 3.0 min) followed by a ramp 
of 7.0 oC/min to a final temperature of 230 oC (held for 6.0 min). 
The mass spectrometer was used in scan mode from 33 to 400 m/z.
Chromatographic data were converted to NetCDF format for 
baseline correction, noise elimination, and peak alignment using 
MetAlign (Lommen 2009). Resulting multivariate data (consisting 
of all mass spectrometric responses exceeding a predefined threshold 
at each scan event) were further processed with the MSClust tool 
for mass spectra extraction and generation of individual selected ion 
chromatogram peak responses (Tikunov et al. 2012). Peak responses 
were scaled to the response of l-carvone, the internal standard. The 
resulting data set, arising from 201 urine sample analyses, consisted 
of a single scaled response per chromatographic peak identified in 
the headspace, which were submitted to statistical analyses.
Statistical analyses and data handling
Analyses were performed in R 3.0.2 (R Development Core Team 
2013) using the lme4 package (Bates et al. 2015) for LMEM and 
multcomp package (Hothorn et al. 2008) for subsequent post hoc 
t-tests. P values below 0.05 were considered statistically significant.
Cytokine data
Successful activation of the immune system by LPS injection in urine 
donors was assessed using AUC measures. Between-treatment (LPS 
and Placebo) comparisons were carried out for each cytokine with 
2-sided Welch’s t-tests. These analyses were conducted on the larger 
group of donors included in chromatographic analyses (n = 31). Due 
to technical problems, plasma samples from 1 donor were missing 
(n = 30; 18 LPS, 12 Placebo).
Perceptual discrimination data
Discriminability of Pre and Post urine was compared between LPS 
and Placebo treatments using a paired t-test of mean number of cor-
rect trials.
Perceptual ratings data
To assess the effects of treatment on perceived dimensions of urine 
odor, linear mixed-effects models (LMEM) were constructed with 
Treatment (LPS and Placebo) and Time (Pre and Post) as fixed ef-
fects and Participant and Donor identity as random effects, which 
accounted for inter-participant differences in rating behavior and 
inter-donor differences in endogenous odor. One participant who 
misunderstood the rating procedure for perceived disgust was ex-
cluded from that model. All perceptual VAS ratings were natural 
log-transformed before analysis, and statistical results are reported 
in linear terms.
Chromatographic data
All carvone-scaled peak responses were subjected to principal com-
ponents analysis using Unscrambler (CAMO Software) to visually 
identify outlier samples exhibiting undue influence or leverage in re-
sidual plots. Nine of the 201 samples were identified as outliers, and 
removal of these resulted in an absence of any posttreatment sam-
ples for 2 donors, thereby effectively excluding those donors from 
further analysis. Samples from 31 donors were retained—19 donors 
from the LPS condition (13 women, 26.1 ± 5.6 years, range: 20.1–
41.1 years) and 12 donors from the Placebo condition (7 women, 
27.6 ± 4.9 years, range: 20.5–35.2 years). Donor age did not differ 
significantly between conditions [t(25.87) = 0.77, P = 0.446]. Among 
retained sample data, means from repeated chemical analyses of the 
same urine sample were calculated for each carvone-scaled peak 
response. Treatment differences were calculated for each donor by 
subtracting mean Pre responses from mean Post responses. To reduce 
the number of variables for analysis, the VARCLUS procedure in SAS 
was used to group the 42 difference responses into related clusters. 
Component scores were then calculated from VARCLUS scoring co-
efficients and standardized differences using the SCORE procedure 
(SAS). Seven component scores were subjected to multivariate ana-
lysis of variance with univariate ANOVA to determine which clus-
ters were impacted by treatment (the lone between-subjects effect). 
The individual chemical variables contributing to significant clusters 
were identified. Standardized mean peak responses for these indi-
vidual chemical variables were submitted to LMEM analyses con-
structed with Treatment (LPS and Placebo) and Time (Pre and Post) 
as fixed effects and Donor identity as a random effect.
Results
Verification of an inflammatory response in donors
Successful triggering of the innate immune system was demon-
strated by significant LPS-induced increases in AUC measures 
of plasma cytokine concentrations, relative to Placebo: TNF-α, 
t(17.122) = 4.21, P = 0.0006; IL-6, t(17.184) = 4.393, P = 0.0004; 
IL-8, t(17.043) = 3.697, P = 0.0018; and IL-10, t (17.319) = 5.24, 
P < 0.0001 (Figure 1).
Perceptual discrimination
Results from the discrimination tasks (Figure 2) indicated that the 
perceptual discriminability differed significantly between treatments 
[LPS = 4.24 correct trials ± standard deviation 1.87, 38.5 ± 17.0%; 
Placebo = 5.71 ± 1.76, 51.9 ± 16.0%; t(20) = 2.62, P = 0.016], with 
participants correctly discriminating Post from Pre in more Placebo 
than LPS trials.
Perceptual ratings
A significant interaction of Treatment (LPS and Placebo) and Time 
(Pre and Post) on perceived urine odor intensity, χ2(1)  =  5.64, 
P = 0.018, was mirrored by a statistical trend for perceived donor 
sickness, χ2(1) = 3.33, P = 0.068, but not for odor disgustingness, 
χ2(1) = 2.61, P = 0.106, and pleasantness, χ2(1) = 0.19, P = 0.666 
(Figure 3). The nominal pattern of results suggests that the natural 
decrease in urine odor averseness observed in Placebo donors over 
the day was disrupted by LPS treatment, rendering postinjection LPS 
samples more aversive than their Placebo counterparts.
As the correlations between the 4 types of ratings were high (abso-
lute values between 0.52 and 0.80), a factor analysis was conducted, 
indicating a single factor solution (absolute factor loadings between 
0.69 and 0.92). A factor score—indicating levels of intensity, pleas-
antness, disgust, and donor sickness—was calculated for each trial. 
Another analysis, like that described earlier, revealed a significant 
interaction of Treatment and Time on the factor score, χ2(1) = 4.36, 
P  =  0.037. In accordance with the results above, the factor score 
tended to decrease from the Pre- to the Post-measurement, but less 
so for LPS-treated participants (Figure 4).
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Chemometric analysis
Urine samples were submitted to chemical analysis and subse-
quent chromatographic data processing to assess the pattern 
of treatment effects on the volatile profile. Cluster analysis re-
vealed 7 clusters, ranging from 22 compounds to 2 compounds. 
Analysis of cluster scores indicated that there was a significant 
treatment effect for only 1 of the 7 clusters (P  =  0.015). The 
3 odorants comprising this cluster were chromatographic peaks 
identified by comparison to known standards as: acetophenone, 
pyrrole, and benzaldehyde. Analysis with LMEM revealed sig-
nificant or statistical trends for the interaction of Treatment 
(LPS and Placebo) and Time (Pre and Post) for acetophenone, 
χ2(1) = 10.79, P = 0.001; pyrrole, χ2(1) = 8.75, P = 0.003; and 
benzaldehyde, χ2(1)  =  3.08, P  =  0.079. In short, pyrrole and 
acetophenone were significantly more abundant following LPS 
treatment, as indicated by Figure 5.
Discussion
The results presented here suggest that within hours of exposure to 
even a relatively weak immune challenge, acute inflammation can 
induce changes to human urine odor that are detectable by both 
human and chemical assays.
More specifically, the results revealed a natural rhythm—a pat-
tern over time—of decreasing urine odor averseness through the day 
(from morning [Pre] to midday [Post] collections), a change that is 
disrupted by upregulation of the innate immune system. The time 
Figure 1. Levels of cytokines (pg/ml). Error bars denote standard error of the mean.
Figure 2. Number of correct discriminations of Pre and Post urine for LPS 
and Placebo samples. Error bars denote standard error of the mean, and the 
asterisk indicates significance (*P < 0.05).
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course of this natural rhythm, observed in Placebo urine, is un-
surprising given the well-established facts that the kidneys’ glom-
erular filtration rate decreases overnight and increases during the 
day (Koopman et al. 1989) and that a significant proportion of the 
human urine metabolome exhibits a diurnal rhythm (Giskeødegård 
et al. 2015).
Figure 4. The factor score—reflecting a hypothesized latent variable for levels of intensity, pleasantness, disgust, and donor sickness—for Pre and Post urine for 
LPS and Placebo samples. Error bars denote standard error of the mean, and the asterisk indicates significance (*P < 0.05).
Figure 3. Perceptual ratings of Pre and Post urine for LPS and Placebo samples. Error bars denote standard error of the mean, the asterisk indicates significance 
(*P < 0.05). The scales for ratings range from 0 “Not at all” to 10 “Most imaginable,” with the exception of the scale for pleasantness, which ranges from −5 “Most 
unpleasant imaginable” to 5 “Most pleasant imaginable.”
716 Chemical Senses, 2018, Vol. 43, No. 9
Although it remains to be conclusively demonstrated what medi-
ated the difference in discriminability of Pre and Post urine between 
the healthy, Placebo and LPS treatments, our chemometric data and 
perceptual ratings offer enticing clues. In the absence of inflamma-
tion, the chemometric data revealed a natural decrease in pyrrole 
abundance from Pre to Post collection times—a change sufficient 
for linear discriminant models to differentiate Post from Pre Placebo 
urine. This decrease in pyrrole abundance was absent under LPS 
treatment. The perceptual ratings may reflect this natural drop of 
pyrrole abundance in the decrease of perceived intensity observed 
posttreatment for Placebo, but not LPS, samples (Figure 3). This sug-
gests that pyrrole may be a urinary volatile with a diurnal rhythm 
that is interrupted by activation of the innate immune system, re-
sulting in higher-than-normal pyrrole levels in Post LPS urine sam-
ples. LPS did induce a significant change in the urinary volatile 
profile in the form of increased acetophenone abundance. No such 
change in acetophenone abundance was seen in Placebo samples, 
suggesting that this increase is because of treatment alone rather 
than to any natural rhythmic changes.
By what mechanism(s) inflammation alters endogenous odor vol-
atiles is not well known (Arakawa et  al. 2011), especially not for 
the time scale investigated here (hours). The innate immune system, 
which is reliably activated by the canonical stimulus LPS, has repeat-
edly been linked to endogenous odors both in animals (Beauchamp 
et al. 1985; Beauchamp and Yamazaki 2005; Arakawa et al. 2010) 
and in humans (Olsson et al. 2014), but whether the effects demon-
strated in this study are directly mediated by inflammatory processes 
cannot be conclusively demonstrated. However, the 2 odorous vol-
atiles, pyrrole and acetophenone, that were significantly elevated as 
a function of LPS have previously been suggested as biomarkers for 
various diseases and pathogen infections. The metabolite pyrrole has 
been identified as elevated in the metabolic disorder phenylketon-
uria disorder (Burke et al. 1983). Increases in urine concentrations of 
acetophenone have previously been indicated in the mouse models of 
lung cancer (Matsumura et al. 2010). How elevated levels of pyrrole 
and acetophenone and activation of the immune system are linked is 
currently not clear. However, based on their known involvement in 
different pathologies, it is conceivable that these 2 odorous volatiles 
together enabled discrimination between treatments in the cluster 
model, not as disease- or pathogen-specific cues but rather as indica-
tors of the general inflammatory response.
An understanding of the perception of health—or sickness—as 
a complex process of integrating multiple sensory cues, often from 
multiple sensory modalities, is important for appreciating the role 
that even the smallest cues can play in contributing to the differen-
tiation of sick and healthy conspecifics. We have demonstrated an 
additive effect of olfactory–visual integration in the perception of 
sickness cues from facial photographs and body odors (Regenbogen 
et al. 2017). And we recently demonstrated (Axelsson et al. 2018) 
that health perception is influenced by a number of subtle visual cues 
of inflammation—such as paleness of the skin and lips, redness of the 
eyes, and droopiness of the eyelids. With knowledge of the role that 
sensory integration plays in health perception, it becomes easier to 
appreciate the potency of disease detection—even during the early 
stages of inflammation when cues may be weak.
These results, akin to animal findings, indicate that there is an 
olfactory cue of inflammation in human urine detectable to conspe-
cifics. The perceived differences of urine odor intensity, sickness, and 
disgustingness indicate that we find the urine of other humans hours 
after onset of an inflammatory response more aversive than the urine 
of healthy counterparts at the same time of day, when baseline (Pre) 
measures are corrected for. The relative differences in abundances of 
pyrrole and acetophenone, and in discriminability between Placebo 
and LPS urine, offer tantalizing glimpses into, respectively, the po-
tential chemical mechanisms that may underpin and the potential 
behavioral consequences that may rest on these perceptual differ-
ences. However, these data do not provide causal links between the 
chemical changes, perceived changes, and discriminability changes.
Future studies, based on these results, can bridge these know-
ledge gaps and refine our description of this inflammation cue 
in human urine by optimizing and narrowing the scope of their 
experimental designs. The putative volatile mediators identi-
fied here, pyrrole and acetophenone, can be targeted directly in 
follow-up studies, thereby avoiding data reduction practices. 
To help mitigate the potential for urine concentration to bias 
between-treatment perceptual or chemometric measures, future 
studies should standardize hydration levels among their urine 
donors. These data, however, appear unaffected by this confound, 
Figure  5. Differences between Pre- and Post-measurements of carvone-normalized pyrrole concentrations and acetophenone concentrations in LPS- and 
Placebo-treated urine. Error bars denote standard error of the mean, AU refers to arbitrary units of differences, and asterisks indicate significance (*P < 0.05, 
**P < 0.01, ***P < 0.001).
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as the chemometric analyses failed to demonstrate any general 
shift in abundancy as a function of LPS treatment. Limiting the 
effects of urine sample preservation by minimizing the handling 
of samples between collection and analysis would also strengthen 
the results of future studies.
The results of this study strengthen the rising view that systemic 
inflammation entails physiological changes that are perceptually de-
tectable to other humans, possibly serving adaptive purposes during 
evolution as a behavioral defense against infectious disease, a central 
threat to survival.
Funding
This work was supported by the Knut and Alice Wallenberg 
Foundation [KAW 2012.0141 to J.N.L.]; the Swedish Research 
Council [421-2012-1125 and 2016–02742 to M.J.O.; 2014-1346 
to J.N.L.]; and the Swedish Foundation for Humanities and Social 
Sciences [P12-1017 to M.J.O.].
Acknowledgements
The authors wish to thank Ms Kelly Dougherty and Mr Jonathan Namini for 
help with data collection.
Conflicts of interest
None.
References
Arakawa H, Arakawa K, Deak T. 2009. Acute illness induces the release of 
aversive odor cues from adult, but not prepubertal, male rats and sup-
presses social investigation by conspecifics. Behav Neurosci. 123:964–978.
Arakawa H, Arakawa K, Deak T. 2010. Sickness-related odor communication 
signals as determinants of social behavior in rat: a role for inflammatory 
processes. Horm Behav. 57:330–341
Arakawa H, Cruz S, Deak T. 2011. From models to mechanisms: odorant 
communication as a key determinant of social behavior in rodents during 
illness-associated states. Neurosci Biobehav Rev. 35:1916–1928.
Axelsson J, Sundelin T, Olsson MJ, Sorjonen K, Axelsson C, Lasselin J, 
Lekander M. 2018. Identification of acutely sick people and facial cues of 
sickness. Proc Biol Sci. 285. doi: 10.1098/rspb.2017.2430
Bates D, Mächler M, Bolker B, Walker S. 2015. Fitting linear mixed-effects 
models using lme4. J Stat Software. 67:1–48.
Beauchamp GK, Yamazaki K. 2005. Individual differences and the chemical 
senses. Chem Senses. 30(1 Suppl):i6–i9.
Beauchamp GK, Yamazaki K, Wysocki CJ, Slotnick BM, Thomas L, Boyse EA. 
1985. Chemosensory recognition of mouse major histocompatibility types 
by another species. Proc Natl Acad Sci U S A. 82:4186–4188.
Beutler BA. 2009. TLRs and innate immunity. Blood. 113:1399–1407.
Boesveldt S, Lindau ST, McClintock MK, Hummel T, Lundstrom JN. 2011. 
Gustatory and olfactory dysfunction in older adults: a national probability 
study. Rhinology. 49:324–330.
Boillat M, Challet L, Rossier D, Kan C, Carleton A, Rodriguez I. 2015. The 
vomeronasal system mediates sick conspecific avoidance. Curr Biol. 
25:251–255.
Burke DG, Halpern B, Malegan D, McCairns E, Danks D, Schlesinger P, 
Wilken B. 1983. Profiles of urinary volatiles from metabolic disorders 
characterized by unusual odors. Clin Chem. 29:1834–1838.
Curtis VA. 2014. Infection-avoidance behaviour in humans and other animals. 
Trends Immunol. 35:457–464.
Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. 2008. From 
inflammation to sickness and depression: when the immune system subju-
gates the brain. Nat Rev Neurosci. 9:46–56.
de Groot JHB, Smeets MAM, Kaldewaij A, Duijndam MJA, Semin GR. 2012. 
Chemosignals communicate human emotions. Psychol Sci. 23:1417–1424.
Eggert F, Luszyk D, Haberkorn K, Wobst B, Vostrowsky O, Westphal E, 
Bestmann HJ, Müller-Ruchholtz W, Ferstl R. 1998. The major histocom-
patibility complex and the chemosensory signalling of individuality in hu-
mans. Genetica. 104:265–273.
Ehman KD, Scott ME. 2001. Urinary odour preferences of MHC congenic fe-
male mice, Mus domesticus: implications for kin recognition and detection 
of parasitized males. Animal Behaviour. 62:781–789.
Ehman KD, Scott ME. 2002. Female mice mate preferentially with non-para-
sitized males. Parasitology. 125:461–466.
Freiherr J, Gordon AR, Alden EC, Ponting AL, Hernandez MF, Boesveldt 
S, Lundström JN. 2012. The 40-item Monell Extended Sniffin’ Sticks 
Identification Test (MONEX-40). J Neurosci Methods. 205:10–16.
Fumagalli M, Sironi M, Pozzoli U, Ferrer-Admetlla A, Pattini L, Nielsen R. 2011. 
Signatures of environmental genetic adaptation pinpoint pathogens as the 
main selective pressure through human evolution. PLoS Genet. 7:e1002355.
Giskeødegård GF, Davies SK, Revell VL, Keun H, Skene DJ. 2015. Diurnal 
rhythms in the human urine metabolome during sleep and total sleep de-
privation. Sci Rep. 5:14843.
Hothorn T, Bretz F, Westfall P. 2008. Simultaneous inference in general para-
metric models. Biom J. 50:346–363.
Jones DS, Podolsky SH, Greene JA. 2012. The burden of disease and the chan-
ging task of medicine. N Engl J Med. 366:2333–2338.
Karshikoff B. 2015. Sickness behavior: immune system influences on brain and 
behavior [PhD]. [Stockholm (Sweden)]: Karolinska Institutet.
Karshikoff B, Lekander M, Soop A, Lindstedt F, Ingvar M, Kosek E, Olgart 
Höglund C, Axelsson J. 2015. Modality and sex differences in pain sensi-
tivity during human endotoxemia. Brain Behav Immun. 46:35–43.
Kavaliers M, Colwell DD. 1995a. Discrimination by female mice between the 
odours of parasitized and non-parasitized males. Proc Biol Sci. 261:31–35.
Kavaliers M, Colwell DD. 1995b. Odours of parasitized males induce aversive 
responses in female mice. Anim Behav. 50:1161–1169.
Kiesecker JM, Skelly DK, Beard KH, Preisser E. 1999. Behavioral reduction of 
infection risk. Proc Natl Acad Sci U S A. 96:9165–9168.
Kimball BA, Opiekun M, Yamazaki K, Beauchamp GK. 2014. Immunization 
alters body odor. Physiol Behav. 128:80–85.
Koopman MG, Koomen GC, Krediet RT, de Moor EA, Hoek FJ, Arisz L. 1989. 
Circadian rhythm of glomerular filtration rate in normal individuals. Clin 
Sci (Lond). 77:105–111.
Lommen A. 2009. MetAlign: interface-driven, versatile metabolomics tool for 
hyphenated full-scan mass spectrometry data preprocessing. Anal Chem. 
81:3079–3086.
Lundström JN, Boyle JA, Zatorre RJ, Jones-Gotman M. 2008. Functional 
neuronal processing of body odors differs from that of similar common 
odors. Cereb Cortex. 18:1466–1474.
Lundström JN, Boyle JA, Zatorre RJ, Jones-Gotman M. 2009. The neuronal 
substrates of human olfactory based kin recognition. Hum Brain Mapp. 
30:2571–2580.
Matsumura K, Opiekun M, Oka H, Vachani A, Albelda SM, Yamazaki K, 
Beauchamp GK. 2010. Urinary volatile compounds as biomarkers for lung 
cancer: a proof of principle study using odor signatures in mouse models 
of lung cancer. PLoS One. 5:e8819.
Mitro S, Gordon AR, Olsson MJ, Lundström JN. 2012. The smell of age: percep-
tion and discrimination of body odors of different ages. PLoS One. 7:e38110.
Oaten M, Stevenson RJ, Case TI. 2009. Disgust as a disease-avoidance mech-
anism. Psychol Bull. 135:303–321.
Olsson MJ, Lundström JN, Kimball BA, Gordon AR, Karshikoff B, Hosseini 
N, Sorjonen K, Olgart Höglund C, Solares C, Soop A, et al. 2014. The 
scent of disease: human body odor contains an early chemosensory cue of 
sickness. Psychol Sci. 25:817–823.
Osada K, Yamazaki K, Curran M, Bard J, Smith BPC, Beauchamp GK. 2003. 
The scent of age. Proc Biol Sci. 270:929–933.
Parma V, Gordon AR, Cecchetto C, Cavazzana A, Lundström JN, Olsson MJ. 
2017. Processing of human body odors. In Buettner A, editor, Springer 
handbook of odor. Cham (Switzerland): Springer International. p. 
963–986.
718 Chemical Senses, 2018, Vol. 43, No. 9
Penn DJ, Oberzaucher E, Grammer K, Fischer G, Soini HA, Wiesler D, 
Novotny MV, Dixon SJ, Xu Y, Brereton RG. 2007. Individual and gender 
fingerprints in human body odour. J R Soc Interface. 4:331–340.
Penn D, Potts WK. 1998. Chemical signals and parasite-mediated sexual selec-
tion. Trends Ecol Evol. 13:391–396.
R Development Core Team. 2013. R: a language and environment for stat-
istical computing. (Version 3.0.2). Vienna (Austria): R Foundation for 
Statistical Computing. Retrieved from http://www.R-project.org/
Regenbogen C, Axelsson J, Lasselin J, Porada DK, Sundelin T, Peter MG, 
Lekander M, Lundström JN,Olsson MJ. 2017. Behavioral and neural cor-
relates to multisensory detection of sick humans. Proc Natl Acad Sci U S 
A. 114:6400–6405.
Renault J, Gheusi G, Aubert A. 2008. Changes in social exploration of a 
lipopolysaccharides-treated conspecific in mice: role of environmental 
cues. Brain Behav Immun. 22:1201–1207.
Schaller M, Duncan LA. 2007. The behavioral immune system its evolution 
and social psychological implications. In: Forgas PJ, Haselton MG, von 
hippel W, editors. Evolution and the social mind: evolutionary psychology 
and social cognition. New York: Psychology Press. 293–307.
Shirasu M, Touhara K. 2011. The scent of disease: volatile organic com-
pounds of the human body related to disease and disorder. J Biochem. 
150:257–266.
Tikunov YM, Laptenok S, Hall RD, Bovy A, de Vos RC. 2012. MSClust: a tool 
for unsupervised mass spectra extraction of chromatography-mass spec-
trometry ion-wise aligned data. Metabolomics. 8:714–718.
Wyatt TD. 2014. Pheromones and animal behavior: chemical signals and sig-
natures. 2nd ed. Cambridge (UK): Cambridge University Press.
Yeshurun Y, Sobel N. 2010. An odor is not worth a thousand words: from 
multidimensional odors to unidimensional odor objects. Annu Rev 
Psychol. 61:219–41, C1.
Chemical Senses, 2018, Vol. 43, No. 9 719
